Melanoma was associated with significantly increased odds of developing irBP after ICI treatment (adjusted OR = 3.21; 95% CI, 1.51–6.58) [10], potentially attributable to tumor-specific express of BP180 autoantigen triggering the production of anti-BP180 autoantibodies upon ICI-induced loss of immune tolerance [20]. Here, COL17A1 is linked to melanoma.